CAC
MRNA icon

Cowen and Company’s Moderna MRNA Stock Holding History

Cowen and Company’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,300
Closed -$4.42M – 649
2022
Q4 		$4.42M Buy
+16,300
New +$2.67M 0.46% 34
2022
Q3 		– Sell
-16,300
Closed -$5.04M – 726
2022
Q2 		$5.04M Hold
16,300
– – 0.49% 43
2022
Q1 		$4.54M Hold
16,300
– – 0.44% 42
2021
Q4 		$3.41M Buy
16,300
+3,200
+24% +$936K 0.31% 64
2021
Q3 		$1.67M Buy
+13,100
New +$4.83M 0.08% 109

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cowen and Company's MRNA Position: Q1 2023 in Review

Cowen and Company sold out of Moderna (MRNA) in Q1 2023, closing a stake of 16,324 shares — an estimated $2.93M sold.

Cowen and Company first reported a position in MRNA in Q3 2021 and held it in 6 quarters. The position peaked at $7.42M in Q3 2022. 1,016 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

  • Cowen and Company reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 16,324 Moderna shares in Q1 2023, an estimated $2.93M.
  • Cowen and Company first reported a position in Moderna in Q3 2021 and held it in 6 quarters.
  • Cowen and Company's Moderna position peaked at $7.42M in Q3 2022.
  • 1,016 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.